Evidence of Clinical Effectiveness and Data Requirements

Eileen Navarro, MD, FACP
Lead Medical Officer
Division of Anti-Infective Products
Office of Antimicrobial Products
OND, CDER, FDA
Outline

• Assessing Clinical Effectiveness
  - Adequate and well controlled trials
  - Endpoints of direct clinical benefit

• Data Requirements
  - Content
  - Format
Laws, Regulations, Guidances

- **Statutes** - Congressional bills signed into law
  - Federal Food, Drug, and Cosmetic Act

- **Regulations** – implementing standards for statutes
  - Code of Federal Regulations e.g. 21 CFR sec. 314.50

- **Guidances** - Informal agency statements that represent current agency thinking, not legally binding
Legal Requirement under FFDCA

Sec 505

(a) Need an approved application to market

(b)(1) Application has full reports of investigations to show whether drug is safe and effective and detailed components, composition, methods and controls

(c) FDA must give positive approval (changed in 1962 from 1938 - then NDA became effective if FDA did not respond)
The Food, Drug and Cosmetic Act of 1938

Required premarket notification.
Required a demonstration of safety for approval.

Basis of refusal:

(a) did not include ALL tests reasonably applicable to show whether drug is safe when used under proposed labeling
(b) testing shows drug unsafe or do not show that it is safe
(c) information submitted or any other information available are insufficient to determine whether safe
(d) labeling is false or misleading in any particular
Keyfauver Harris Amendments 1962

1. FDA had to actively grant approval before a drug could be marketed

2. Requirement to study drugs under an IND; informed consent

3. The effectiveness requirement: Substantial evidence that the drug will have the effect it purports or is represented to have under proposed labeled conditions of use.
Drug Regulation History

- 1970s drug lag
- 1980s public health needs – clamor for access to investigational drugs (HIV epidemic)
- PDUFA 1992 – specific timelines S/P 10/6 months
- FDAMA 1997 – fast track for drugs for serious disease AND fill an unmet need
- FDAAA 2007 – authorities for safety assessment
- FDASIA 2012 – generic drug/medical device UFAs GAIN, QIDP, breakthrough, standards mandates, etc
LABELING 21CFR 201.56-57

Labeling must bear adequate directions for use and may not be false or misleading.

Very critical to support requirements for dose-response and individualization information (21 CFR 314.50 mandates for safety and effectiveness – age, gender, [race])
LABELING 21CFR 201.56-57

Law requires labeling providing adequate directions for use. A basis for asking for data on

- individualization
- dose-response
- drug-drug interactions
- subpopulation analyses

Physician Labeling Rule
- Revised format; highlights section
- Pregnancy section

Guidance on ADR’s, Clinical Trials, Warnings/Precautions
Aims of NDA/BLA review

• Assess a biologic for purity, identity, safety and potency

• Assess a drug to be safe and effective
Clinical Effectiveness

505d Substantial evidence consists of adequate and well-controlled investigations including clinical investigations...on the basis of which it could be concluded that the drug will have the effect it is represented to have under the conditions of use proposed in labeling.

FDAMA 1997 – allow 1 study (with confirmatory evidence) in certain select circumstances
Effectiveness – “clinically meaningful” added in court

Guidance on clinical effectiveness – May 1998
Regulations that affect an NDA Submission

21CFR 314.50: Content & Format of an Application

21CFR 314.126: Adequate & Well-Controlled Studies

21CFR 314.500: Accelerated approval (use of surrogate endpoints and approval with restrictions)
Evidence

Well controlled studies of adequate design must show effectiveness, *ordinarily* a STATISTICALLY significant effect on a CLINICALLY meaningful endpoint, usually replicated, as a basis for approval.

Robert Temple
Adequate and Well-Controlled Studies

Trial should measure drug effect, not spontaneous change or influence of unacknowledged bias

Therefore, trials should be of ADEQUATE design where the CONTROL group is essentially identical to test group except exposure to test agent

Minimize bias favoring either treatment group in how test and control are selected, treated, observed or analyzed

pre-study, during and post study

DESIGN CONDUCT and ANALYSIS

Study reports should provide sufficient detail regarding the design, interventions, how the study was done and the results.
Characteristics of an AWC Trial
Cliff notes version

- PRE-define a win, and in some cases, by how much (endpoint, timing, analytic population, SAP)
- Design permits quantitative comparison with the control (powered)
- Adequate exclusion/inclusion
- Minimize bias in assignment - adequate randomization to assure baseline comparability of treatment groups
- Adequacy of blinding/ allocation concealment
clear statement of the objectives of the investigation. protocol should contain a description of the proposed methods of analysis, and the study report should contain a description of the methods of analysis ultimately used. if the protocol does not contain a description of the proposed methods of analysis, the study report should describe how the methods used were selected.

the study uses a design that permits a valid comparison with a control to provide a quantitative assessment of drug effect. the protocol for the study and report of results should describe the study design precisely; for example, duration of treatment periods, whether the treatments are parallel, sequential, or crossover, & whether the sample size is predetermined or based upon interim analysis.

the method of selection of subjects provides adequate assurance that they have the disease or condition being studied, or evidence of susceptibility and exposure to the condition

the method of assigning patients to treatment and control groups minimizes bias and is intended to assure comparability of the groups with respect to pertinent variables such as age, sex, severity of disease, duration of disease, and use of drugs or therapy other than the test drug. the protocol for the study and the report of its results should describe how subjects were assigned to groups. ordinarily, in a concurrently controlled study, assignment is by randomization, with or without stratification.

adequate measures are taken to minimize bias on the part of the subjects, observers, and analysts of the data. the protocol and report of the study should describe the procedures used to accomplish this, such as blinding.

the methods of assessment of subjects’ response are well-defined and reliable. the protocol for the study and the report of results should explain the variables measured, the methods of observation, and criteria used to assess response.

there is an analysis of the results of the study adequate to assess the effects of the drug. the report of the study should describe the results and the analytic methods used to evaluate them, including any appropriate statistical methods. the analysis should assess, among other things, the comparability of test and control groups with respect to pertinent variables, and the effects of any interim data analyses performed.
Well-Controlled Studies
21 CFR 314.126

- Placebo control
- No treatment concurrent control
- Dose-response control
- Active Control
- Historical Control
Measuring Drug Effect (AWC)

SUPERIORITY studies allows a direct measure of drug effect, but not always feasible to conduct (superiority to placebo may not be ethical or superiority to active control may not be achievable).

\[ \text{Drug - placebo} = \text{attributable effect (M)} \]

If the trial intends to show similarity (NONINFERIORITY) of the test and control drugs, the report should assess the ability of the study to have detected a difference between treatments, should one exist.

\[ \text{Drug} = \text{comparator with known drug effect (Drug-P)} \]
Noninferiority Trials

Desire to use equivalence is understandable: seems sensible to compare new and old effective therapy. Avoids exposure to ineffective treatment.

Fundamental distinction between trials intended to show a difference and trials intended to show similarity; latter pose major problems of interpretation.

Similarity of test drug and active control can mean either that both drugs were effective or that neither was effective.
Favors Test \hspace{1cm} \leftrightarrow \hspace{1cm} Favors Control

Control - Test
Treatment Effect of Fluconazole in EC

Fluconazole - Placebo
Noninferiority of Micafungin to Fluconazole in EC

Endpoint: endoscopic cure

Fluconazole - Micafungin

-60  -40  -20  0  20  40  60

-5.9  -0.3  5.3
ENDPOINTS: Definition & characteristics

Distinct and measurable characteristics used to assess the outcome of therapeutic interventions

21 CFR 314.126(b)(6) “The methods of assessment of subjects’ response are well-defined and reliable.”

Well defined “treatment benefit = effect on how a patient survives, feels or functions. ..other measures that do not capture these are surrogate measures of benefit”

Endpoints – consider implications in context of study design

• Composite Endpoints – multiple ways to win
  - When outcomes are discordant
  - Which component drives a win
  - Which component is sensitive to drug effect

• Measuring Endpoints
  - Patient Reported Outcomes, Biomarkers

• Methods of Collection
  - Standards enhance replication, balance with flexibility
Congress intended to require at least two adequate and well-controlled studies, each convincing on its own, to establish effectiveness.

“In most drug development programs, the need to find an appropriate dose, to study patients of greater and lesser complexity or severity of disease, to compare the drug to other therapy, to study an adequate number of patients for safety purposes, and to otherwise know what needs to be known about a drug before it is marketed will result in more than one adequate and well-controlled study upon which to base an effectiveness determination.”

“Guidance on Clinical Effectiveness”
One Adequate & Well Controlled Study

Relied on single excellent multicenter study with statistically strong finding, or where there was an important clinical benefit, (for example, such clear superiority in mortality), making a confirmatory study difficult to conduct on ethical grounds.

SO, A VERY HIGH BAR to conduct a SINGLE AWC study.
Regulatory Flexibility: Clinical Effectiveness Guidance

Extrapolation (no efficacy studies of required) e.g. bioequivalence, pediatric studies

One adequate and well controlled study + independent substantiation
**(CONFIRMATORY study)**
- Efficacy study of different dose, regimen or form
- Efficacy in another disease phase
- Efficacy in another population
- Combination or monotherapy
- Efficacy in a closely related disease
- Efficacy in unrelated disease but where purpose is similar
- Efficacy in different endpoints
- Pharmacologic/pathophysiologic correlation

One study **(NO CONFIRMATORY DATA NEEDED)**
- Multicenter study - no single site provides large fraction of patients & drives the result & consistency across study subsets is seen - demographic, severity etc
- Multiple studies in a single study (Factorial studies)
- Multiple endpoints involving different events
- Statistically very persuasive finding
Guidance: Concepts for Expedited Programs for Serious Conditions

Serious Condition: defined in Accelerated Approval Regulations (57 FR 58942, 1992) as conditions that as “a matter of clinical judgment, impact survival, day to day functionality, or likelihood that if left untreated progress to more serious one” [21 CFR312.300(b)(1)]. Life threatening as defined in 21 CFR 312.81(a) would also be serious.

Covers the following programs: Fast Track Designation, Accelerated Approval, Breakthrough Designation

Eligible products- “intended to have an effect on a serious aspect of a condition, such as a direct effect on a serious manifestation or symptom of a condition, or other intended effects, including:

• A diagnostic product intended to improve diagnosis or detection of a serious condition that lead to improved outcomes
• A product intended to improve/prevent a serious treatment-related side effect (e.g., serious infections from immunosuppression)
• A product intended to avoid a serious adverse effect associated with available therapy for a serious condition (e.g., less cardiotoxicity than available cancer therapy)”

https://www.federalregister.gov/articles/2013/06/26/2013-15250/draft-guidance-for-industry-on-expedited-programs-for-serious-conditions-drugs-and-biologics

*superseded Guidance for Industry: Fast Track Drug Development Program –Designation, Development and Review
Unmet need = treatment or diagnosis not addressed ADEQUATELY by available therapy, immediate need for a defined population or “a longer term need for society” (development or resistance in antibacterial drugs)

Existing or available therapy = approved or licensed in the United States for the same indication being considered for the new drug AND is relevant to current US standard of care (standard of care) for the indication, “only in rare cases will a treatment that is not approved ...or is not FDA-regulated (e.g. surgery) be considered available therapy. (This ) constitutes available therapy when the safety and effectiveness of the use is supported by compelling evidence, including evidence in published literature” (e.g. cancer). Recommendations from authoritative scientific bodies based on AWC or other “reliable” information and consultation with SGEs can inform US SOC.

https://www.federalregister.gov/articles/2013/06/26/2013-15250/draft-guidance-for-industry-on-expedited-programs-for-serious-conditions-drugs-and-biologics
*superceded Guidance for Industry: Fast Track Drug Development Program –Designation, Development and Review
Guidance: Concepts for Expedited Programs for Serious Conditions

A range of potential advantages beyond those shown in head to head comparisons will be considered - Even when not shown to have an efficacy or safety advantage – “a novel mechanism of action with a well-understood relationship to the disease pathophysiology. When a reasonable basis for concluding that a significant number of patients may respond differently to the new drug compared to available therapy may be a basis for this designation. For example, mechanistic diversity, even without a documented efficacy or safety advantage, could be advantageous in disease settings in which drugs become less effective or ineffective over time.” As well it is preferable to have more than one treatment approved under accelerated approval regulations because benefit may not be verified in confirmatory trials for already approved products.

https://www.federalregister.gov/articles/2013/06/26/2013-15250/draft-guidance-for-industry-on-expedited-programs-for-serious-conditions-drugs-and-biologics
*superseded Guidance for Industry: Fast Track Drug Development Program –Designation, Development and Review
<table>
<thead>
<tr>
<th>Fast Track</th>
<th>Breakthrough</th>
<th>Accelerated Approval</th>
<th>Priority Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potential to address unmet need (nonclinical and clinical) OR Preliminary clinical evidence of substantial improvement over available therapies on clinical endpoint</td>
<td>Meaningful therapeutic benefit over available therapies on a surrogate endpoint reasonably likely to predict benefit or on early clinical endpoint likely to predict IMM</td>
<td>Significant improvement in safety or effectiveness or labeling supplement on pediatric 505A or designated QIDP or submission w/ a priority voucher</td>
<td></td>
</tr>
<tr>
<td>Can submit with IND, no later than pre NDA Can submit with IND, no later than EOP2</td>
<td>Discuss with division</td>
<td>With BLA, NDA, supplement</td>
<td></td>
</tr>
<tr>
<td>Fast Track</td>
<td>Breakthrough</td>
<td>Accelerated Approval</td>
<td>Priority Review</td>
</tr>
<tr>
<td>------------</td>
<td>--------------</td>
<td>---------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Actions to expedite development and review (rolling)</td>
<td>Intensive guidance from phase 1 Organizational commitment involving senior management</td>
<td>Assessment on an endpoint earlier than the definitive endpoint the surrogate is likely to predict</td>
<td>Shorter review clock (6 months)</td>
</tr>
<tr>
<td>Designation may be withdrawn if no longer meets criteria</td>
<td>Designation may be withdrawn if no longer meets criteria</td>
<td>Promotional materials review Conduct required postapproval trials to verify benefit or effect on IMM Subject to withdrawal</td>
<td>Designation at the time of filing</td>
</tr>
</tbody>
</table>
Fast Track

• FDAMA 1997 - process
• Drugs for serious disease AND fill an unmet need (Superior effectiveness, avoid serious side effects, improve diagnosis, reduce toxicity)
• Can be requested at any time during development, respond in 60 days
• Meetings, written correspondence, eligibility (not guarantee) for accelerated approval and rolling review, dispute resolution
Accelerated Approval
21 CFR 314.500

Approval based on a surrogate endpoint “that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence to predict clinical benefit”.

Conditions:
1. Serious or life-threatening illness
2. Meaningful benefit over existing treatments
3. Requirement to study the drug post-approval to “verify and describe its clinical benefit”.
Priority Review

• 1992 PDUFA FDA agreed to goals for drug review times
  - Standard review = 10 month clock
  - Priority review = 6 month clock

• Criteria:
  - Increased effectiveness in treatment, prevention, diagnosis,
  - elimination or reduction of treatment-limiting drug reaction,
  - documented enhancement of patients willingness or ability to take the drug according to required schedule and dose
  - safety & effectiveness in new subpopulation, ex children
Subpart H Accelerated Approval

- 1992 (21 CFR 314.500) regulation
- “Reasonable likely to predict” vs “survives, feels or functions”
- Surrogate vs direct clinical benefit; studies need to be AWC, needs confirmatory studies
- If confirmatory studies demonstrate direct clinical benefit, traditional approval is granted, could lead to removal
Requirements 21 CFR 314 Subpart I

• (1) Postmarketing studies.
• (2) Approval with restrictions to ensure safe use.
  - (i) Restricted distribution to certain facilities/ trained health care practitioners
  - (ii) Distribution conditioned on performance of specified medical procedures,
    (iii) Distribution conditioned on specified recordkeeping requirements.
• (3) Information to be provided to patient recipients.
  labeling must explain that, for ethical or feasibility reasons, the
drug's approval was based on efficacy studies conducted in
animals alone and must give the drug's indication(s), directions
for use (dosage and administration), contraindications, a
description of any reasonably foreseeable risks, adverse
reactions, anticipated benefits, drug interactions, and any other
relevant information
Guidance/Advice

Written Guidances

Open Advisory Committee meetings

Availability of reviews after drug is approved
Critical Guidance

1. ICH E3 “Structure and Content of Clinical Study Reports” reporting an important trials and integrated analyses of the efficacy and safety data, which are required under 314.50
2. E4 - Dose-Response Information to Support Drug Registration
3. E5 - Ethnic Factors (Really, what additional data should be requested if submitted data are extra-regional)
4. E6 - GCP’s
5. E9 - Statistical Principles for Clinical Trials
6. E10 – Choice of Control Group
7. E-14 – Clinical Evaluation of QT/QTc
8. Clinical Evaluation by Therapeutic Category (Indication Specific)
9. Special Population, Genomic
Content and Format of an Application (21 CFR 314.50),
ICH Common Technical Document

Module 1
(1) application form
(3) annotated text of proposed labeling
(3) table of contents

Module 5
(1) human pharmacokinetics
(2) microbiology
(3) clinical data
(4) statistical section
(7) pediatric use
(8) CRF and CRT

http://www.fda.gov/cder/regulatory/gov
Clinical Section 21 CFR 314.50

1. Description and analysis of every controlled study, including protocol and statistical analysis, sufficient reports of everything pertinent to safety and effectiveness from any source.

2. Integrated data summary of substantial evidence of effectiveness and evidence to support dosage and administration, modifications for subgroups (pediatrics, geriatric, renal failure).

3. Safety summary & updates (4 months prior to approval) of with all available information (animal data, adverse effects, drug-drug interactions).
Clinical Section (continued)

4. Case report forms for deaths and discontinuations due to AEs (thought drug related or not). Others on request. Prior to 1985, all CRFs required

5. Case report tabulations. (replaced “all CRFs”)
   All data from well-controlled studies
   All data from earliest clinical pharmacology studies
   Safety data from other studies
Data = Information = Knowledge = Understanding
Common Technical Data Format

Modules
- M1: Administrative Information
- M2: Summaries
- M3: Quality, i.e.: CMC
- M4: Non-clinical Studies
- M5: Clinical Trials
Modules M1 and M2

- **M1: Administrative Information**
  - Cover letter (1.2)
  - Administrative information (1.3)
  - Meetings (1.6) minutes of Agency-Sponsor interactions
  - Special Protocol Assessments (1.8); may also be in (1.6)
  - Annual Reports (1.13) especially if marketed elsewhere
  - Labeling (1.14)

- **M2: Summaries (all disciplines)**
  - Clinical overview (2.5)
  - Clinical summary (2.7)
    - Summary of Clinical Safety (2.7.4) - *not* the ISS
    - Summary of Clinical Efficacy (2.7.3) - *not* the ISE
Module M5

M5: Clinical Study Reports

- Tabular listing of clinical studies (5.2)
- Protocols and amendments (5.3.5.1.4)
- Case Report Forms (CRFs) (5.3.5.1.24)
- Clinical Trial Reports (CSRs) (5.3.5.1.3)

• Integrated Summary of Safety (ISS)
• Integrated Summary of Efficacy (ISE)

• Datasets (5.3.5.1.25)
  - Electronic datasets (5.3.5.1.25.3)
  - Define files (5.3.5.1.25.3.3)

Guide to submission and analyses
describe & document files
select analyses, key variables
handling missing data

Document study conduct and outcome
adjudication
Orig & amended protocol
SAP (efficacy/safety), DSMB
& adjudication charters,
meetings and deliberations
randomization list , addtl
investigator instructions
Clinical Filing Checklist for Day 45 meeting:

- Are datasets available for all pivotal trials?
- Are they reliable, transparent and traceable to the CRF?
- Do the datasets reflect the Sponsor’s report of dosage, treatment arms, adequate exposure of doses and duration?
- Are the datasets in a format to allow review of patient data? Are endpoints, adverse events evaluable?
- Is the raw data available to derive the composite endpoints? Do the data allow replication of findings?
- Request data needed that is not submitted
- Pick the trial sites for audit
Clinical Filing Checklist - selected sections:

<table>
<thead>
<tr>
<th>Content Parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FORMAT/ORGANIZATION/LEGIBILITY</strong></td>
</tr>
<tr>
<td>1. Identify the general format that has been used for this application, e.g. <strong>electronic CTD</strong>.</td>
</tr>
<tr>
<td>2. On its face, is the clinical section organized in a manner to allow substantive review to begin?</td>
</tr>
<tr>
<td>3. Is the clinical section indexed (using a table of contents) and paginated in a manner to allow substantive review to begin?</td>
</tr>
<tr>
<td>4. For an <strong>electronic submission</strong>, is it possible to navigate the application in order to allow a substantive review to begin <em>(e.g., are the bookmarks adequate)</em>?</td>
</tr>
<tr>
<td>5. Are all documents submitted in English or are English translations provided when necessary?</td>
</tr>
<tr>
<td>6. Is the clinical section legible so that substantive review can begin?</td>
</tr>
<tr>
<td><strong>LABELING</strong></td>
</tr>
<tr>
<td>7. Has the applicant submitted the design of the development package and <strong>draft labeling in electronic format</strong> consistent with current regulation, divisional, and Center policies?</td>
</tr>
</tbody>
</table>
Clinical Filing Checklist - selected sections:

<table>
<thead>
<tr>
<th>DATASETS</th>
</tr>
</thead>
<tbody>
<tr>
<td>31. Has the applicant submitted datasets in a format to allow reasonable review of the patient data?</td>
</tr>
<tr>
<td>32. Has the applicant submitted datasets in the format agreed to previously by the Division?</td>
</tr>
<tr>
<td>33. Are all datasets for pivotal efficacy studies available and complete for all indications requested?</td>
</tr>
<tr>
<td>34. Are all datasets to support the critical safety analyses available and complete?</td>
</tr>
<tr>
<td>35. For the major derived or composite endpoints, are all of the raw data needed to derive these endpoints included?</td>
</tr>
</tbody>
</table>

February 2012: Final Rule in PDUFA V requiring e-submissions in standard format
From [FDA.GOV](https://www.fda.gov) - Search “electronic submissions guidances” and click on first result.

Below is a sortable listing of Electronic Submissions Guidances:

<table>
<thead>
<tr>
<th>Category</th>
<th>Title</th>
<th>Type</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic Submissions</td>
<td>Part 11, Electronic Records, Electronic Signatures — Scope and Application (PDF - 215KB)</td>
<td>Final Guidance</td>
<td>00/02/08</td>
</tr>
<tr>
<td>Electronic Submissions</td>
<td>Indexing Structured Product Labeling (PDF - 59KB)</td>
<td>Final Guidance</td>
<td>00/02/08</td>
</tr>
<tr>
<td>Electronic Submissions</td>
<td>Providing Regulatory Submissions in Electronic Format — Content of Labeling (PDF - 28KB)</td>
<td>Final Guidance</td>
<td>04/20/05</td>
</tr>
<tr>
<td>Electronic Submissions</td>
<td>Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing (PDF - 123KB)</td>
<td>Final Guidance</td>
<td>05/28/09</td>
</tr>
<tr>
<td>Electronic Submissions</td>
<td>Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (PDF - 133KB)</td>
<td>Final Guidance</td>
<td>06/11/08</td>
</tr>
<tr>
<td>Electronic Submissions</td>
<td>Providing Regulatory Submissions in Electronic Format; General Considerations (PDF - 54KB)</td>
<td>Final Guidance</td>
<td>01/01/09</td>
</tr>
<tr>
<td>Electronic Submissions</td>
<td>Providing Regulatory Submissions in Electronic Format – General Considerations (PDF - 280KB)</td>
<td>Draft Guidance</td>
<td>10/01/03</td>
</tr>
<tr>
<td>Electronic Submissions</td>
<td>Providing Regulatory Submissions in Electronic Format – Postmarketing Individual Case Safety Reports (PDF - 377KB)</td>
<td>Draft Guidance</td>
<td>06/12/06</td>
</tr>
</tbody>
</table>
How will CDISC standards help the clinical reviewer?

- **Predictability across submissions** - information will be where you expect it to be, and variables will mean the same. For example:
  - Outcomes
  - Adverse events
  - Demographics
  - Concomitant meds (WHO drug dictionary)

- **Higher quality data (CDISC)**
  - Increased transparency in the review process
  - Data omissions are evident

- **Identify issues early in review period**
  - Domain names may be unfamiliar and variable names non-standard (e.g.: PTNO for USUBJID).

- **Validation of study results facilitated by standard analytics using new review tools**
Study Data Standards for Submission to CDER

CDER strongly encourages IND sponsors and NDA applicants to consider the implementation and use of data standards for the submission of applications. Such implementation should occur as early as possible in the product development lifecycle, so that data standards are accounted for in the design, conduct, and analysis of studies. These resources are intended to assist submitters in the preparation and submission of standardized study data to CDER. This webpage will be updated regularly to reflect CDER’s growing experience in order to meet the needs of its reviewers.

- **CDER Data Standards Common Issues Document** (PDF - 115KB) - The goal of this document is to communicate general CDER preferences and experiences regarding the submission of standardized data to aid sponsors in the creation of standardized datasets. The document is not intended to replace the need for sponsors to communicate with review divisions regarding data standards implementation approaches or issues, but instead, it is designed to complement and facilitate the interaction between sponsors and divisions.

- **Study Data Specifications (v1.6)** (PDF - 199KB) - Study specifications for submitting animal and human study datasets in electronic format.

- **CDISC Study Data Tabulation Model (SDTM)**
  - **SDTM Implementation Guide for Human Clinical Trials (SDTM IG)** - Developed by the Clinical Data Interchange Standards Consortium (CDISC), the SDTM IG is an implementation of the SDTM for clinical study data. The conceptual model and SDTM IG can be obtained from the CDISC website at: [http://www.cdisc.org/SDTM](http://www.cdisc.org/SDTM)
  - **Standard for Exchange of Nonclinical Data Implementation Guide (SEND IG)** - Developed by the Clinical Data Interchange Standards Consortium (CDISC), the SEND IG is an implementation of the SDTM for data collected from animal toxicology studies.
  - The production version of the SEND Implementation Guide (IG) Version 3.0 (SEND IG v3.0) is NOW available at [http://www.cdisc.org/send](http://www.cdisc.org/send)

- **CDISC Analysis Data Model (ADaM)** - Developed by the Clinical Data Interchange Standards Consortium (CDISC), ADaM is an analysis dataset standard accepted by CDER. The Model and Implementation Guide can be obtained from the CDISC website at: [http://www.cdisc.org/adam](http://www.cdisc.org/adam)

**Technical Assistance**
- Questions regarding datasets should be forwarded to the CDER eDATA team at cder-edata@fda.hhs.gov.
Annotated CRF

Domain names of datasets relevant to this CRF page

Variable names relevant to this CRF page
Conclusions

• Adequate and well controlled studies are the basis for a successful NDA; planning starts in IND
• Adequate evidence is rooted in science, codified in regulation, validated in review, described in label
• GCP is reflected in quality submissions; standards facilitate labeling of efficacy and safety
Thanks!

Slides from colleagues and OND/CDER training